Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer anti-hyperglycaemic drug matters? - PubMed (original) (raw)
Review
. 2020 Feb;22(2):149-157.
doi: 10.1111/dom.13881. Epub 2019 Oct 17.
Affiliations
- PMID: 31495989
- DOI: 10.1111/dom.13881
Review
Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer anti-hyperglycaemic drug matters?
Dario Giugliano et al. Diabetes Obes Metab. 2020 Feb.
Abstract
We are observing a resurgence of major diabetic vascular complications after a period of dramatic decrease during the period 1990 to 2010. The classical division of cardiovascular prevention into primary (with an event) and secondary (without an event) is largely used to describe cardiovascular risk in type 2 diabetes (T2D); however, there is evidence that the cardiovascular risk in diabetes may range from highest in patients who experienced a previous cardiovascular event to mild in patients with the main risk factors at target. Herein, we present details of the 14 cardiovascular outcome trials (CVOTs) published to date, including the total population investigated, and their separation into primary (T2D + multiple risk factors) and secondary prevention (T2D + established cardiovascular disease [CVD]) populations as detailed within the trials. We also summarize evidence for the effects of dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP1-RA) and sodium glucose co-transporter-2 inhibitors (SGLT-2i) versus placebo on the risk of major cardiovascular events (MACE), heart failure (HF) and diabetic kidney disease (DKD). In primary prevention, SGLT-2i reduce both the risk of hospitalization for HF and progression of DKD; in secondary prevention, SGLT-2i are effective on the three endpoints, DPP-4i are neutral, while GLP1-RA show mixed results.
Keywords: CVOTs; MACE; cardiovascular prevention; diabetic kidney disease; heart failure; primary prevention; secondary prevention.
© 2019 John Wiley & Sons Ltd.
Similar articles
- Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials.
Giugliano D, Maiorino MI, Longo M, Bellastella G, Chiodini P, Esposito K. Giugliano D, et al. Endocrine. 2019 Jul;65(1):15-24. doi: 10.1007/s12020-019-01931-y. Epub 2019 Apr 26. Endocrine. 2019. PMID: 31028667 - The residual cardiorenal risk in type 2 diabetes.
Giugliano D, Maiorino MI, Bellastella G, Esposito K. Giugliano D, et al. Cardiovasc Diabetol. 2021 Feb 5;20(1):36. doi: 10.1186/s12933-021-01229-2. Cardiovasc Diabetol. 2021. PMID: 33546683 Free PMC article. - Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. Zelniker TA, et al. Circulation. 2019 Apr 23;139(17):2022-2031. doi: 10.1161/CIRCULATIONAHA.118.038868. Circulation. 2019. PMID: 30786725 - Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials.
Giugliano D, De Nicola L, Maiorino MI, Bellastella G, Esposito K. Giugliano D, et al. Diabetes Obes Metab. 2019 Aug;21(8):1790-1800. doi: 10.1111/dom.13743. Epub 2019 May 2. Diabetes Obes Metab. 2019. PMID: 30969018 Review. - Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope.
Giugliano D, Meier JJ, Esposito K. Giugliano D, et al. Diabetes Obes Metab. 2019 May;21(5):1081-1087. doi: 10.1111/dom.13629. Epub 2019 Feb 14. Diabetes Obes Metab. 2019. PMID: 30609236 Review.
Cited by
- Role of Albuminuria in Detecting Cardio-Renal Risk and Outcome in Diabetic Subjects.
Pafundi PC, Garofalo C, Galiero R, Borrelli S, Caturano A, Rinaldi L, Provenzano M, Salvatore T, De Nicola L, Minutolo R, Sasso FC. Pafundi PC, et al. Diagnostics (Basel). 2021 Feb 12;11(2):290. doi: 10.3390/diagnostics11020290. Diagnostics (Basel). 2021. PMID: 33673215 Free PMC article. Review. - The Role of Echocardiography in Evaluating Cardiovascular Diseases in Patients with Diabetes Mellitus.
Lee SH, Park JH. Lee SH, et al. Diabetes Metab J. 2023 Jul;47(4):470-483. doi: 10.4093/dmj.2023.0036. Epub 2023 Jul 27. Diabetes Metab J. 2023. PMID: 37533197 Free PMC article. Review. - Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney.
Giugliano D, De Nicola L, Maiorino MI, Bellastella G, Garofalo C, Chiodini P, Ceriello A, Esposito K. Giugliano D, et al. Cardiovasc Diabetol. 2020 Mar 19;19(1):35. doi: 10.1186/s12933-020-01010-x. Cardiovasc Diabetol. 2020. PMID: 32192503 Free PMC article. - Applications of Clinical Decision Support Systems in Diabetes Care: Scoping Review.
Huang S, Liang Y, Li J, Li X. Huang S, et al. J Med Internet Res. 2023 Dec 8;25:e51024. doi: 10.2196/51024. J Med Internet Res. 2023. PMID: 38064249 Free PMC article. - Nephroprotection by SGLT2 Inhibition: Back to the Future?
De Nicola L, Gabbai FB, Garofalo C, Conte G, Minutolo R. De Nicola L, et al. J Clin Med. 2020 Jul 15;9(7):2243. doi: 10.3390/jcm9072243. J Clin Med. 2020. PMID: 32679744 Free PMC article. Review.
References
REFERENCES
- Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271-281.
- Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med. 2014;370:1514-1523.
- Gregg EW, Hora I, Benoit SR. Resurgence in diabetes-related complications. JAMA. 2019;321:1867-1868.
- Paolillo S, Marsico F, Prastaro M, et al. Diabetic cardiomyopathy: definition, diagnosis, and therapeutic implications. Heart Fail Clin. 2019;15:341-347.
- Standard of Medical Care in Diabetes 2019. 10. Cardiovascular disease and risk management. Diabetes Care. 2019;42(suppl1):S103-S123.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous